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Eliminationoflymphaticﬁlariasis(LF)inthePaciﬁcIslandCountriesandTerritories(PICT)hasbeendeﬁnedas<0.1%circulating
ﬁlarial antigen (CFA) prevalence in children born after the implementation of successful mass drug administrations (MDAs). This
research assessed the feasibility of CFA and antibody testing in three countries; Tonga, Vanuatu, and Samoa. Transmission is
interrupted in Vanuatu and Tonga as evidenced by no CFA positive children and a low antibody prevalence and titre. Transmission
is ongoing in Samoa with microﬁlaraemic (Mf) and CFA positive children and a high antibody prevalence and titre. Furthermore,
areas of transmission were identiﬁed with Mf positive adults, but no CFA positive children. These areas had a high antibody
prevalence in children. In conclusion, CFA testing in children alone was not useful for identifying areas of residual endemicity in
Samoa. Thus, it would be beneﬁcial to include antibody serology in the PICT surveillance strategy.
1.Introduction
Lymphatic ﬁlariasis (LF), a mosquito-transmitted parasitic
diseasecausedbytheﬁlarialnematodesWuchereriabancrofti,
Brugia malayi, and Brugia timori, is classiﬁed as a neglected
tropical disease (NTD) that is endemic in many parts of
the world including the South Paciﬁc [1–3]. The Global
Elimination Programme to eliminate LF (GPELF) began
in the late 1990s, and the Paciﬁc counterpart of GPELF,
formed in 1999 under the auspices of the World Health
Organization (WHO), was named the Paciﬁc Programme
for the Elimination of Lymphatic Filariasis (PacELF) [4, 5].
PacELF resolved to eliminate LF as a public health problem
in the Paciﬁc using mass drug administrations (MDAs) [5].
Elimination of LF was deﬁned as <1% circulating ﬁlarial
antigen (CFA) prevalence of the population and <0.1% CFA
prevalence in children born after the implementation of
MDAs [6].
Sixteen of the 22 countries falling under the jurisdiction
of PacELF were classiﬁed as endemic for LF following
baseline prevalence surveys. They were American Samoa, the
Cook Islands, the Federated Statesof Micronesia, Fiji, French
Polynesia, Kiribati, the Marshall Islands, New Caledonia,
Niue, Palau, Papua New Guinea, Samoa, Tonga, Tuvalu,
Vanuatu,andWallisandFutuna[7].TheCookIslands,Niue,
Vanuatu, and Tonga have reached <1% CFA prevalence of
the population following ﬁve rounds of MDA and are now
implementing activities to ensure that transmission has been2 Journal of Tropical Medicine
interrupted and to detect any remaining and/or new foci
of transmission [8]. The challenge for this phase of the LF
programme is to ﬁnd a suitable strategy for surveillance in
those countries that have reached the target threshold.
Recently, child transmission surveys (CTS) have been
proposed as a potential method for surveillance in the South
Paciﬁc as part of the “draft LF active surveillance strategy for
thePaciﬁcIslandCountriesandTerritories(PICT)”[7].This
method relies on detecting CFA positive children in either
school-based or community-based surveys. The strategy was
based on the preapproved LF diagnostic assays available and
took into consideration resource and funding constraints
[7]. Upon detection of a CFA positive child, using the ﬁeld
immunochromatographic test (ICT), surrounding residents
(200m radius or 24 houses) would be tested to identify the
microﬁlaraemic (Mf) positive case from the child’s house of
residence [7]. Since drafting the surveillance strategy, three
South Paciﬁc countries have ﬁnished their CTS, either alone
or in conjunction with post-MDA prevalence surveys. The
CTS was completed in two countries which had entered
surveillance mode, Tonga and Vanuatu, and Samoa, where
transmission was ongoing [8].
As the prevalence of LF declines, the sensitivities of the
gold standards, which measure Mf and CFA, also decrease
[9–13],potentiallymakingtheseassayslessusefulduringthis
stage of the LF elimination programme [14–16]. Antibody
responses to LF exposure have been suggested as an ideal
immunologicalmeasurementforidentifyingareasofresidual
endemicity in future surveillance campaigns [9, 14, 17–19].
Previous studies demonstrated that antibody production in
response to LF exposure occurs during the ﬁrst few years of
life [20]. Therefore, children born after the cessation of LF
transmission should be antibody negative [17, 21–27]. One
standardised diagnostic tool for the detection of antibodies
is the Filariasis Cellabs Enzyme Linked Immunosorbent
Assay (CELISA). This diagnostic assay measures antiﬁlarial
IgG4 and is adaptable for both serum samples and ﬁlter
paper samples with little interlaboratory variation [28,
29]. Antibody serology can be used in conjunction with
seroprevalence mapping, which has been demonstrated to be
useful for visualising problem areas where exposure occurs
[30].
Filariasis control began in Tonga in 1977, and by
1999, when Tonga joined PacELF, the CFA prevalence
w a sr e c o r d e da s2 . 7 %( http://www.wpro.who.int/pacelf/
programmes/ton/PacELF+Activities+to+Date.htm). MDA
rounds were completed annually in Tonga for ﬁve years from
2001 to 2005 with reported coverage rates of 79%, 84%,
91%, 86%, and 85%, respectively, [8]. Following the ﬁfth
round of MDA, Tonga recorded an overall CFA prevalence of
0.4% and, therefore, completed its CTS in 2007. The results
are presented in this paper.
By 2005, Vanuatu had completed its ﬁfth round
ofMDA(http://www.wpro.who.int/pacelf/programmes/van/
activities.htm). The annual rounds were from 2000 to 2004
with reported coverage rates of 83%, 84%, 84%, 87%,
and 85%, respectively, [8]. Following the ﬁnal round of
MDA in 2005, countrywide CFA prevalence was 0.32%,
with no detectable Mf positives (Vanuatu country report,
unpublished data)[ 8]. Consequently, Vanuatu completed its
CTS in 2007, the results of which are presented in this paper.
Samoa has a long history of ﬁlariasis control; initial
ﬁlariasis surveys began as early as the 1920s, with attempts
at control programmes in the 1940s [4]. In 1966, MDAs
began and Samoa completed 10 rounds of MDA before the
establishment of PacELF [31, 32]. In 1999, Samoa was the
ﬁrst country to implement the new MDA regimen using a
combinationofdiethylcarbamazinecitrate(DEC)andalben-
dazole [4]. A further six rounds of MDA were completed
from 1999 to 2006. The reported MDA coverage for the ﬁve
rounds conducted from 1999 to 2003 was 90%, 57%, 68%,
60%, and 80%, respectively, [8]. In 2004, a stratiﬁed cluster
nationwide survey demonstrated an overall Mf prevalence
of 0.4% with a CFA prevalence of 1.1%. This corresponded
to a 75.6% reduction in CFA positive individuals since the
beginning of the new national programme in 1999 [4, 5].
The results from the follow-up survey in 2007 are presented
in this paper in conjunction with the 2007 CTS.
The aim of this research was to determine if the presence
ofCFApositivechildrenaloneaccuratelyreﬂectedacessation
of LF transmission, as assumed in the draft surveillance
strategy, or if it was necessary to complement CFA testing
with antibody serology using the Filariasis CELISA. By
doing so, we help contribute to deﬁning a cessation of LF
transmission and early detection of possible resurgence as
part of active surveillance. This will assess the potential of
the Filariasis CELISA to be incorporated into the repertoire
of available LF diagnostic assays currently used in LF
eliminationprogrammes.Serologicalmappingcouldthenbe
used to easily identify and visualise areas where exposure is
ongoing and where further investigations could be required
by the country LF programme managers [33].
2.MaterialsandMethods
2.1. Study Population. Three South Paciﬁc countries, Samoa,
Tonga, and Vanuatu, participated in the study in 2007. The
study was conducted under Human Ethics Approval number
H1423, as approved by the James Cook University Research
Human Ethics Committee.
2.1.1. Samoa. The post-MDA prevalence survey was a
national survey conducted by health district, across both
Savai’i and Upolu using the stratiﬁed cluster method. Strati-
ﬁed cluster sampling was performed by dividing the country
into implementation units (IUs) within which villages were
chosen randomly [6]. Within the village, a minimum of ﬁve
households were randomly chosen. Participants of any age
were asked to register, and blood samples were taken. All
participants were bled for ICT testing and those that tested
ICT positive were rebled for Mf testing. Filter paper samples
were also collected from children aged 5 to 10 years for
antibody serology. Overall, the survey included 6648 people,
with 2315 children ≤10 years. Of these children, 1045 were
included in antibody testing.
2.1.2. Tonga. CTS carried out in Tonga was in accordance
with the “draft LF active surveillance strategy for the PICT”Journal of Tropical Medicine 3
using the school-based approach [7], but with the addition
of antibody serology. Blood collection occurred in primary
schools across the islands of ‘Eua, Ha’apai, and Vava’u.
Overall, 797 children aged 5 to 6 years participated in the
study. All participants were bled for ICT testing and those
that tested ICT positive were rebled for Mf testing. Filter
paper samples were also collected for antibody serology.
2.1.3. Vanuatu. A total of 3840 children aged 5 to 6 years
were bled across the country in accordance with the CTS
outlined in the “draft LF active surveillance strategy for the
PICT” using the community-based approach [7], but with
the addition of antibody serology. These children were bled
for ICT and those positive were bled for Mf testing. Filter
paper samples were also collected for antibody serology.
2.2. Blood Collection. Following registration and informed
verbal consent, approximately 220μL of blood was collected
by ﬁngerprick. One hundred microlitres was used for CFA
testingintheﬁeld.IftheICTtestwaspositive,60μLwasused
to make a three-line thick blood smear for Mf examination.
The remaining blood was soaked onto the six protrusions
of a Tropbio ﬁlter paper disc, each holding 10μL of blood
(Tropbio Pty Ltd, QLD, Australia). The ﬁlter paper disc
w a sd r i e d ,p l a c e di nz i p l o c kb a g s ,a n dt r a n s p o r t e db a c kt o
Australia for storage at −20◦C until testing for antiﬁlarial
antibodies.
2.3. Circulating Filarial Antigen Testing. The ﬁeld test to
detect CFA was the NOW ﬁlariasis Immunochromato-
graphic test (ICT) and performed according to the manufac-
turer’s instructions as previously described (Binax, Portland,
ME, USA) [34]. Brieﬂy, the collected 100μL of blood was
transferred onto the absorbent pad using the capillary tube
and the result was read at exactly 10 minutes, according to
the manufacturer’s instructions, and recorded as positive,
negative, or invalid. Positives (referred to as CFA positive)
were rebled for Mf examination.
2.4. Microﬁlaremia Testing. Blood taken from a ﬁngerprick
was smeared into three lines, approximately 20μL thick,
onto a microscope glass slide using a capillary as previously
described [35] .T h es l i d e sw e r el e f tt od r yf o r4 8h o u r s
then wrapped for transport. In the laboratory of each
country, each slide was stained in 10% Giemsa stain (20
minutes), washed in water, dried, then coverslipped. The
slide was examined under the microscope (×200), and Mf
were recorded. The number of Mf per mL of blood was
calculatedbasedontheinitial60μLvolume.Bloodcollection
for Mf testing in Vanuatu and Tonga occurred between 2200
and 0100 hours. Blood collection for Mf testing in Samoa
occurred between 0800 and 2000 hours according to peak
levels of Mf and biting tendencies of Aedes polynesiensis [36].
2.5. Antibody Testing with the Filariasis CELISA. Antiﬁlarial
IgG4 antibodies were detected using the Filariasis CELISA
kit (Cellabs Pty Ltd, Manly, Australia). One protrusion
of ﬁlter paper was eluted overnight at 4◦C in 500μLo f
sample diluent. The following morning, the elution was
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Figure 1: Prevalence rates of the diagnostic parameters: Mf,
CFA, and antibody in children. There was a signiﬁcantly lower
antibody (Ab) prevalence in children in Vanuatu and Tonga and
a signiﬁcantly higher antibody prevalence in children in Samoa
(χ2 = 549.3; df = 3; P<0.001). There were no Mf or CFA positive
children detected in either Vanuatu or Tonga.
thoroughly vortexed and assayed in duplicate, according
to the manufacturer’s instructions. The washing steps were
performed with an automated plate washer (MultiDrop
Combi nL, Pathtec, VIC, Australia) using 200μLp e rw e l l .
Plates were read at a dual wavelength of 450nm and 650nm
withaMultiskanEXType355PrimaryV.2.1-0(Pathtec,VIC,
Australia) using the software Labsystems Genesis Version
3.00(Pathtec,VIC,Australia).Negativesamplesweredeﬁned
asODvalue<0.260,andpositivesamplesweredeﬁnedasOD
value ≥0.400 [28]. Samples with values between these OD
values were repeated, in accordance with the manufacturer’s
instructions, and if the OD value was <0.400, they were
considered negative. Antibody prevalence was based on
positive/negative reactivity of the samples. Antibody titres
were assumed to correspond to the OD absorbance value
[37].
2.6. Statistical Analysis and Prevalence Mapping. All data
was entered into SPSS Statistical Software Package Ver-
sion 17.0. Prevalence rates were calculated using the
descriptive options in SPSS, and 95% Conﬁdence Interval
(CI) was calculated using the JavaStat binomial software
(http://statpages.org/conﬁnt.html) and included in the ﬁg-
ures. Chi-squared test was used to investigate the diﬀerence
in prevalence rates among countries and health districts
in Samoa. The Kruskall-Wallis test for nonparametric data
was used to compare the OD absorbance values (antibody
titres)amongthethreecountries.PrevalenceofMf,CFA,and
antibody in Samoa was mapped using CorelDRAW.
3. Results
3.1. Study Population. In Vanuatu and Tonga, all children
testednegative forCFA, whereasin Samoathere wereMfand
CFA positive children detected (Figure 1). This was coupled4 Journal of Tropical Medicine
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Figure 2:Diﬀerencesinantibodytitreinantibody-positivechildren
residinginSamoa,Tonga,andVanuatu.Ofthosechildrenwhowere
antibody positive, there was a signiﬁcantly higher average antibody
titre in Samoa than Vanuatu and Tonga (χ2 = 41; df = 2; P = 0).
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Figure 3: Mf, CFA, and antibody prevalence across the health
districts in Samoa. Leulumoega 1 recorded a signiﬁcantly higher Mf
(∗), CFA (∗), and antibody (Ab) prevalence in children (∗) than
the other districts (χ2 = 46.9; df = 6; P<0.001), (χ2 = 124.9;
df = 6; P<0.001), (χ2 = 20.6; df = 6; P<0.001). Similarly,
Palalui recorded a signiﬁcantly high antibody (Ab) prevalence (∗∗)
in children (χ2 = 20.6; df = 6; P<0.001).
with a signiﬁcantly lower antibody prevalence recorded for
both Vanuatu (6.0%) and Tonga (6.3%) when compared to
Samoa (30.7%) (P<0.001, Figure 1). In addition, of those
childrenwhowereantibodypositive,therewasasigniﬁcantly
higher average antibody titre in Samoa than Vanuatu and
Tonga (P = 0, Figure 2). Consequently in Samoa, the overall
signiﬁcantly higher antibody prevalence and titre, coupled
with Mf and CFA positive children, was further analysed
by health district to identify potential residual areas of
endemicity.
3.1.1. Samoa. When analysing the data by health district,
Leulumoega 1, on Upolu, had a signiﬁcantly higher Mf
prevalence (2%) (P<0.001) and CFA prevalence (7.3%)
(P<0.001, Figure 3). Furthermore, including Palalui,
Leulumoega 1 had a signiﬁcantly higher antibody prevalence
in children (44.9%) (P<0.001, Figure 3). There were three
health districts with detectable Mf positive adults, but no
CFA positive children (Safotu (0.2%) and Tuasivi (0.3%)
on Savai’i and Leulumoega 2 (0.4%) on Upolu). In these
areas, Mf prevalence exceeded 0.1%, the deﬁned threshold
for ongoing transmission [6], and the antibody prevalence in
children exceeded 20%. Prevalence for the three parameters
was easily visualised on the geographical maps, including
residual endemic areas in the aforementioned districts
(Figure 4).
When analysing the data for children only, Upolu main-
tained a signiﬁcantly higher CFA prevalence (P = 0.043), yet
no diﬀerences were observed for Mf prevalence between the
islands (P = 0.218, Figure 5). For the health districts, Mf
positive children were found only in Leulumoega 1, which
had a signiﬁcantly higher antibody prevalence (Figure 3)
and the highest CFA prevalence, although not signiﬁcantly
higher than the other villages with CFA positive children
(P = 0.271). Luﬁluﬁ and Palalui were the other 2 villages
with CFA-positive children (Figure 5).
4. Discussion and Conclusions
Active LF surveillance requires accurate and sensitive diag-
nostic assays to detect residual areas of endemicity and
resurgence early. The current draft LF active surveillance
strategy for the PICT [7] relies solely on CFA testing in chil-
dren, since the use of antibody serology is not yet currently
approved [6]. This is due to the need for standardisation,
which can now be achieved using the commercially available
Filariasis CELISA (Cellabs Pty Ltd). It was the aim of this
research to assess the validity of the current surveillance
strategy and if incorporating antibody serology would be
advantageous in the PICT. The ﬁrst aim of the research was
partially addressed, but until long-term monitoring of the
outcomes of the elimination programme occurs, the strategy
will continue to be dynamic to meet individual country
needs.
The data indicated the cessation of LF transmission in
both Tonga and Vanuatu and ongoing LF transmission in
Samoa. In Tonga and Vanuatu, there were no detectable CFA
positive children coupled with a signiﬁcantly low antibody
prevalence and titre. Identiﬁcation of Mf and CFA positive
children in Samoa was coupled with a signiﬁcantly higher
antibody prevalence and titre. For Vanuatu and Tonga,
the higher value of antibody prevalence (6%) versus the
CFA prevalence (0%) is a reﬂection of the sensitivity and
speciﬁcity of the Filariasis CELISA for ﬁlter paper sampling.
When using ﬁlter paper samples, the Filariasis CELISA has a
positive predictive value (PPV) of 60% (95% CI = 43–75)
[28]. This means that a false positive is expected at a rate
of approximately 40% (95% CI = 25% to 57% of the time)
[28]. Filter paper samples have inherent higher OD values
[38], but it would be disadvantageous to use serum for wide-
scale programmatic sampling because of the diﬃculties with
collection and storage [28]. The higher PPV of the FilariasisJournal of Tropical Medicine 5
Safotu
Tuasivi
Palalui
Luﬁluﬁ
Leulumoega
Savai’i
Upolu
0 5 10 20
(Km)
0–0.99
1–5
5.01–10
10.01–15
0–0.99
1–5
5.01–10
10.01–15
15.01–20
20.01–25
Safotu
Tuasivi
Palalui
Savai’i
Safotu
Tuasivi
Palalui
Savai’i
Leulumoega
Leulumoega
Luﬁluﬁ
Luﬁluﬁ
Upolu
Upolu
0–15
15.01–20
20.01–30
30.01–40
40.01–50
50.01–60
60.01–100
Roads
N
E
S
W
Mf (%) CFA (%) Antibody (%)
Figure 4: Serological mapping for Mf, CFA, and antibody prevalence across Samoa. Geographical mapping allows quick reference to
suspected problem areas or “hot spots” of residual endemicity.
CELISA does not impact on the usefulness of the diagnostic
assay from a programmatic perspective, since recent research
has demonstrated the use of the assay for identifying clusters
of exposed children [39]. It could be suggested that it would
be appropriate for the country programme managers to
follow up any identiﬁed clusters of exposed children with
a more in-depth serological study using the gold standard
serum. This would be on a smaller and more manageable
scale than the programmatic survey.
Previous studies in Egypt, where the vector Culex sp.i s
endemic [40], suggest a <2% antibody prevalence in ﬁrst-
year primary school children as a threshold for elimination
[25]. This study did indicate the potential necessity for
diﬀerent threshold targets for other endemic areas. The
data presented here does not concur with a 2% antibody
prevalence threshold for interruption of transmission in the
PICT since both Vanuatu and Tonga recorded prevalence
rates of 6% and transmission was interrupted. However,
the studies in Egypt used serum samples with laboratory-
based ELISAs, not ﬁlter paper samples with the commercial
Filariasis CELISA.
The detection of ongoing transmission in Samoa was
furtheranalysedbyeachhealthdistricttoassessifthecurrent
surveillance strategy could identify problem areas. CFA test-
ing alone in children (CTS) was not adequate for identifying
all of the key residual areas of endemicity in Samoa. There
were three health districts with detectable Mf positive adults,
but no CFA positive children, where transmission would
likely be occurring. This is because in these health districts
Mf prevalence exceeded 0.1%, the recommended threshold
by WHO for the interruption of transmission [6] and spatial
clustering of LF has been previously identiﬁed [39]. The
health districts identiﬁed were Safotu and Tuasivi on the
island of Savai’i and Leulumoega 2 on the island of Upolu.
In these health districts, the antibody prevalence in children
exceeded 20%, an observation compatible with ongoing
exposure. Very importantly, it must be emphasised that these
health districts would not have been detected as areas of
residual or reemerging infection based on CFA testing in
children alone and would have been missed if the proposed
WHO surveillance programme using ICT testing was in
place. These signiﬁcant foci were only identiﬁed because6 Journal of Tropical Medicine
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Figure 5: Mf, CFA, and antibody prevalence in children ≤10 years
only across the health districts in Samoa. Similar to the data across
all ages groups, Upolu had a signiﬁcantly higher CFA prevalence
in children than Savai’i (χ2 = 4.086; df = 1; P = 0.043). No
diﬀerences for Mf prevalence were observed between the two island
groups (χ2 = 1.514; df = 1; P = 0.218). Similarly, no signiﬁcant
diﬀerences for Mf prevalence were observed among the health
districts (χ2 = 10.694; df = 6; P = 0.098), since Mf positive
children were identiﬁed only in Leulumoega 1. Complementing
this result, Leulumoega 1 recorded a signiﬁcantly higher antibody
(Ab) prevalence (∗) than the other districts (χ2 = 20.6; df = 6;
P<0.001). The health districts of Aua, Leulumoega 2, Safotu,
and Tuasivi recorded no CFA positive children. There were no
signiﬁcant diﬀerences for CFA prevalence in children among the
health districts (χ2 = 2.612; df = 2; P = 0.271).
antibody serology was included in the testing protocol.
Therefore, it would be beneﬁcial to strengthen the current
strategy surveillance strategy by including antibody serology.
In Samoa, the identiﬁcation of Mf and CFA positive chil-
dren is indicative of ongoing transmission, which is further
evidenced by a signiﬁcantly higher antibody prevalence and
titre in children. These ﬁndings support previous studies
whereby Samoa exceeded 1% CFA prevalence following ﬁve
rounds of MDA [8]. The reasons for ongoing transmission
in Samoa are yet to be ascertained, but it is crucial that these
are addressed in order for LF elimination to be successful.
It has been suggested that lack of directly observed therapy
(DOT), lack of compliance, and lack of vector control could
all be contributing factors [8, 31, 41, 42]. Recent research has
indicated the potential for vector control in Samoa which
will have a positive impact on the Samoan LF elimination
programme [39]. The seroprevalence maps in the current
study could provide the Samoan LF programme managers
with a starting point to further investigate residual endemic
areas and potentially incorporate vector control.
In addition, the results from the current study indicate
that antibody prevalence thresholds need to be comple-
mentedwithanalysingantibodytitres,sincethelowantibody
prevalence in Tonga and Vanuatu was coupled with a signif-
icantly low antibody titre in positive children. Collectively,
low prevalence and low titre (with no detectable antigen-
positive children) suggest an interruption of transmission.
During active surveillance mode, the detection of an area
with low antibody prevalence but high antibody titre could
require further investigation.
In conclusion, transmission of LF has been interrupted
in Tonga and Vanuatu as evidenced by no detectable
CFA positivity in children and signiﬁcantly low antibody
prevalence and titres. Ongoing transmission of LF is evident
in Samoa based on the presence of Mf/CFA positive children
and a signiﬁcantly high antibody prevalence and titres. Most
importantly, key residual areas of endemicity, which can also
be observed by seroprevalence mapping, would have been
overlooked when testing for CFA positivity alone in children.
This holds promise for future incorporation of antibody
prevalence mapping in the current surveillance strategy for
the PICT.
Acknowledgments
The authors would like to thank the Ministries of Health in
Samoa, Tonga, and Vanuatu. They would like to thank the
cartographer,AdellaEdwards,andherassistant,JulianLawn,
for drawing the maps of Samoa. They would like to thank
Dr. Petra Buttner for her statistical advice. Lastly, we would
like to thank GlaxoSmithKline for their generous ongoing
ﬁnancial support of the LF support centre at the James Cook
University.
References
[1] P. J. Lammie, A. Fenwick, and J. Utzinger, “A blueprint
for success: integration of neglected tropical disease control
programmes,” Trends in Parasitology, vol. 22, no. 7, pp. 313–
321, 2006.
[2] E. Michael and D. A. P. Bundy, “Global mapping of lymphatic
ﬁlariasis,” Parasitology Today, vol. 13, no. 12, pp. 472–476,
1997.
[3] E. A. Ottesen, “Lymphatic ﬁlariasis: treatment, control and
elimination,” Advances in Parasitology, vol. 61, pp. 395–441,
2006.
[4] K. Ichimori and A. Crump, “Paciﬁc collaboration to eliminate
lymphatic ﬁlariasis,” Trends in Parasitology, vol. 21, no. 10, pp.
441–444, 2005.
[5] K. Ichimori, P. M. Graves, and A. Crump, “Lymphatic ﬁlar-
iasis elimination in the Paciﬁc: PacELF replicating Japanese
success,” Trends in Parasitology, vol. 23, no. 1, pp. 36–40, 2007.
[6] WHO, “Monitoring and epidemiological assessment of the
programme to eliminate lymphatic ﬁlariasis at implemen-
tation unit level,” Tech. Rep. WHO/CDS/CPE/CEE 2005.50,
World Health Organization, 2005.
[7] WHO, “Report of the 9th workshop for Paciﬁc lymphatic
ﬁlariasis programme managers,” Tech. Rep. RS/2007/GE/20,
World Health Organization, Fiji, 2007.
[8] C. Huppatz, C. Capuano, K. Palmer, P. M. Kelly, and D.
N. Durrheim, “Lessons from the Paciﬁc programme to
eliminate lymphatic ﬁlariasis: a case study of 5 countries,”
BMC Infectious Diseases, vol. 9, no. 1, article 92, 2009.
[ 9 ]C .A .G r a d y ,M .B .D eR o c h a r s ,A .N .D i r e n ye ta l . ,“ E n d -
points for lymphatic ﬁlariasis programs,” Emerging Infectious
Diseases, vol. 13, no. 4, pp. 608–610, 2007.Journal of Tropical Medicine 7
[10] D. H. Molyneux, “Filaria control and elimination: diagnostic,
monitoring and surveillance needs,” Transactions of the Royal
Society of Tropical Medicine and Hygiene, vol. 103, no. 4, pp.
338–341, 2009.
[11] S. M. Njenga, C. N. Wamae, C. S. Mwandawiro, and D. H.
Molyneux, “Immuno-parasitological assessment of bancrof-
tian ﬁlariasis in a highly endemic area along the River Sabaki,
in Malindi district, Kenya,” Annals of Tropical Medicine and
Parasitology, vol. 101, no. 2, pp. 161–172, 2007.
[12] S. Chanteau, J. P. Moulia-Pelat, P. Glaziou et al., “Og4C3
circulating antigen: a marker of infection and adult worm
burden in Wuchereria bancrofti ﬁlariasis,” Journal of Infectious
Diseases, vol. 170, no. 1, pp. 247–250, 1994.
[13] A. Rocha, D. Addiss, M. E. Ribeiro et al., “Evaluation of
the Og4C3 ELISA in Wuchereria bancrofti infection: infected
personswithundetectableorultra-lowmicroﬁlarialdensities,”
Tropical Medicine and International Health,v o l .1 ,n o .6 ,p p .
859–864, 1996.
[14] C. H. Washington, J. Radday, T. G. Streit et al., “Spatial
clustering of ﬁlarial transmission before and after a Mass
Drug Administration in a setting of low infection prevalence,”
Filaria Journal, vol. 3, no. 1, article 3, 2004.
[15] D. N. Durrheim, T. Nelesone, R. Speare, and W. Melrose,
“Certifying lymphatic ﬁlariasis elimination in the Paciﬁc—the
need for new tools,” Paciﬁc Health Dialog,v o l .1 0 ,n o .2 ,p p .
149–154, 2003.
[16] W. D. Melrose, D. D. Durrheim, and G. W. Burgess, “Update
on immunological tests for lymphatic ﬁlariasis,” Trends in
Parasitology, vol. 20, no. 6, pp. 255–257, 2004.
[17] P. J. Lammie, G. Weil, R. Noordin et al., “Recombinant
antigen-based antibody assays for the diagnosis and surveil-
lance of lymphatic ﬁlariasis—a multicenter trial,” Filaria
Journal, vol. 3, no. 1, article 9, 2004.
[18] R. M. R. Ramzy, M. El Setouhy, H. Helmy et al., “Eﬀect of
yearly mass drug administration with diethylcarbamazine and
albendazole on bancroftian ﬁlariasis in Egypt: a comprehen-
sive assessment,” The Lancet, vol. 367, no. 9515, pp. 992–999,
2006.
[ 1 9 ] S .M .N j e n g a ,C .N .W a m a e ,D .W .N j o m o ,C .S .M w a n d a w i r o ,
andD.H.Molyneux,“Impactoftworoundsofmasstreatment
with diethylcarbamazine plus albendazole on Wuchereria
bancrofti infection and the sensitivity of immunochromato-
graphic test in Malindi, Kenya,” Transactions of the Royal
Society of Tropical Medicine and Hygiene, vol. 102, no. 10, pp.
1017–1024, 2008.
[20] C. L. Gao, W. C. Cao, and X. X. Chen, “Changes in anti-ﬁlarial
antibody after control of ﬁlariasis in Shandong Province,”
Chinese Medical Journal, vol. 107, no. 5, pp. 360–363, 1994.
[21] T. Supali, N. Rahmah, Y. Djuardi, E. Sartono, P. R¨ uckert, and
P. Fischer, “Detection of ﬁlaria-speciﬁc IgG4 antibodies using
Brugia Rapid test in individuals from an area highly endemic
for Brugia timori,” Acta Tropica, vol. 90, no. 3, pp. 255–261,
2004.
[22] J. M. Mladonicky, J. D. King, J. L. Liang et al., “Assessing
transmission of lymphatic ﬁlariasis using parasitologic, sero-
logic,andentomologictoolsaftermassdrugadministrationin
American Samoa,” American Journal of Tropical Medicine and
Hygiene, vol. 80, no. 5, pp. 769–773, 2009.
[23] C. Huppatz, D. Durrheim, P. Lammie, P. Kelly, and W.
Melrose, “Eliminating lymphatic ﬁlariasis—the surveillance
challenge,” Tropical Medicine and International Health, vol. 13,
no. 3, pp. 292–294, 2008.
[24] P. J. Lammie, M. D. Reiss, K. A. Dimock, T. G. Streit, J. M.
Roberts, and M. L. Eberhard, “Longitudinal analysis of the
development of ﬁlarial infection and antiﬁlarial immunity in
a cohort of Haitian children,” American Journal of Tropical
Medicine and Hygiene, vol. 59, no. 2, pp. 217–221, 1998.
[25] G. J. Weil and R. M. R. Ramzy, “Diagnostic tools for ﬁlariasis
elimination programs,” Trends in Parasitology, vol. 23, no. 2,
pp. 78–82, 2007.
[26] R. M. R. Ramzy, H. Helmy, R. Faris, A. M. Gad, R.
Chandrashekar, and G. J. Weil, “Evaluation of a recombinant
antigen-based antibody assay for diagnosis of bancroftian
ﬁlariasis in Egypt,” Annals of Tropical Medicine and Parasitol-
ogy, vol. 89, no. 4, pp. 443–446, 1995.
[27] G. J. Weill, W. Kastens, M. Susapu et al., “The impact of
repeated rounds of mass drug-administration with diethylcar-
bamazine plus albendazole on bancroftian ﬁlariasis in Papua
New Guinea,” PLoS Neglected Tropical Diseases, vol. 2, no. 12,
article e344, 2008.
[28] H. M. Joseph and W. D. Melrose, “Applicability of the ﬁlter
paper technique for detection of antiﬁlarial IgG4 antibodies
using the Bm14 Filariasis CELISA,” Journal of Parasitology
Research, vol. 2010, Article ID 594687, 6 pages, 2010.
[29] G. J. Weil, K. C. Curtis, P. U. Fischer et al., “A multicenter
evaluation of a new antibody test kit for lymphatic ﬁlariasis
employing recombinant Brugia malayi antigen Bm-14,” Acta
Tropica. In press.
[30] M. Booth, B. J. Vennervald, L. C. Kenty et al., “Micro-
geographical variation in exposure to Schistosoma mansoni
and malaria, and exacerbation of splenomegaly in Kenyan
school-aged children,” BMC Infectious Diseases, vol. 4, article
13, 2004.
[31] T. R. Burkot, G. Taleo, V. Toeaso, and K. Ichimori, “Progress
towards, and challenges for, the elimination of ﬁlariasis from
Paciﬁc-island communities,” Annals of Tropical Medicine and
Parasitology, vol. 96, supplement 2, pp. S61–69, 2002.
[32] K. Ichimori, P. Tupuimalagi-Toelupe, V. T. Iosia, and P.
Graves, “Wuchereria bancrofti ﬁlariasis control in Samoa
before PacELF (Paciﬁc Programme to Eliminate Lymphatic
Filariasis),” Tropical Medicine and Health,v o l .3 5 ,n o .3 ,p p .
261–269, 2007.
[33] M. Booth and D. W. Dunne, “Spatial awareness in parasite
immuno-epidemiology,” Parasite Immunology, vol. 26, no. 11-
12, pp. 499–507, 2004.
[34] G. J. Weil, P. J. Lammie, and N. Weiss, “The ICT ﬁlariasis
test: a rapid-format antigen test for diagnosis of bancroftian
ﬁlariasis,” Parasitology Today, vol. 13, no. 10, pp. 401–404,
1997.
[35] M. Sasa, Human Filariasis: A Global Survey of Epidemiology
and Control, University Park Press, Baltimore, Md, USA, 1976.
[36] S. Ramalingam, “The epidemiology of ﬁlarial transmission in
Sanoa and Tonga,” Annals of Tropical Medicine and Parasitol-
ogy, vol. 62, no. 3, pp. 305–324, 1968.
[ 3 7 ]J .S .D y l e w s k i ,L .R a s m u s s e n ,J .M i l l s ,a n dT .C .M e r i g a n ,
“Large-scale serological screening for cytomegalovirus anti-
bodies in homosexual males by enzyme-linked immunosor-
bent assay,” Journal of Clinical Microbiology,v o l .1 9 ,n o .2 ,p p .
200–203, 1984.
[38] E. C. De Haas, A. Di Pietro, K. L. Simpson et al., “Clinical
evaluation of M30 and M65 ELISA cell death assays as
circulating biomakers in a drug-sensitive tumor, testicular
cancer,” Neoplasia, vol. 10, no. 10, pp. 1041–1048, 2008.
[39] H. Joseph, J. Moloney, F. Maiava, S. McClintock, P. Lammie,
and W. Melrose, “First evidence of spatial clustering of
lymphatic ﬁlariasis in an Aedes polynesiensis endemic area,”
Acta Tropica. In press.8 Journal of Tropical Medicine
[40] G. J. Weil, R. M. R. Ramzy, M. El Setouhy, A. M. Kandil, E.
S. Ahmed, and R. Faris, “A longitudinal study of Bancroftian
ﬁlariasis in the Nile Delta of Egypt: baseline data and one-
year follow-up,” American Journal of Tropical Medicine and
Hygiene, vol. 61, no. 1, pp. 53–58, 1999.
[41] D. Kyelem, G. Biswas, M. J. Bockarie et al., “Determinants of
success in national programs to eliminate lymphatic ﬁlariasis:
a perspective identifying essential elements and research
needs,” American Journal of Tropical Medicine and Hygiene,
vol. 79, no. 4, pp. 480–484, 2008.
[42] H. Joseph, A. Clough, A. Peteru et al., “Exploratory study
investigating factors inﬂuencing mass drug administration
(MDA) compliance for lymphatic ﬁlariasis in Samoa,” Samoa
Medical Journal, vol. 2, no. 3, pp. 12–25, 2010.